Maggie Tibbitt

Articles

Hypoxic Storage Could Extend Red Blood Cell Life, Thereby Reduce Transfusion Frequency in Hematologic Malignancies

December 18th 2021

Steven L. Spitalnik, MD, discusses the evolution of red blood cell storage and the potential impact the Hemanext storage technique could have for patients with hematologic malignancies.

Real-World Data Underscores Efficacy of Durvalumab in NSCLC

December 17th 2021

Real-world data from the PACIFIC-R trial evaluating durvalumab following chemoradiotherapy in patients with stage III, unresectable non–small cell lung cancer provide evidence supporting the agent’s efficacy in this population, solidifying its role as a standard-of-care treatment

Enrollment in Histologically-Specific Trials Improves Outcomes in Soft Tissue Sarcoma

December 16th 2021

Elise Nassif, MD, discusses the evolving standard of care for patients with soft tissue sarcoma and the benefits of early phase inclusion, as well as histotype testing for this population.

Hypoxic Blood May Improve Outcomes for Patients With MDS Requiring Transfusions

December 11th 2021

Paul M. Ness, MD, discusses the goal of the Hemanext ONE® blood storage system and the potential benefit of this approach for those with myelodysplastic syndrome and other conditions that require transfusions.

MRD-Guided Treatment Represents the Future in CLL

December 6th 2021

William G. Wierda, MD, PhD, discussed the results of the phase 2 CAPTIVATE trial and the phase 1/2 TRANSCEND CLL 004 trial, and looked ahead to what the future holds for MRD in patients with CLL.

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma

December 6th 2021

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.

Ribociclib/Everolimus Elicits Responses in Dedifferentiated Liposarcoma

December 5th 2021

Margaret von Mehren, MD, discusses the value of ribociclib plus everolimus for patients with dedifferentiated liposarcoma, and how further research will be focused on biomarker analysis.

The Evolving Role of Prognostic Markers for CLL in the Era of Novel Agents

December 3rd 2021

Deborah M. Stephens, DO, discusses her approach to treating a patients with chronic lymphocytic leukemia, how CAR T-cell therapy may fit into the treatment paradigm, and the numerous trials that have shown promise in this space.

Retifanlimab Shows Promising Antitumor Activity in Advanced Endometrial Cancer

December 1st 2021

Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.

Hochster Shares Best Practices on Molecular Markers and Sequencing in Gastric Cancer

November 29th 2021

Howard S. Hochster, MD, discusses molecular markers for patients with gastric cancer, using gene expression profiles as biomarkers, and choosing between anti–PD-1 and anti–CTLA-4 agents.

Incorporating Mutational Panel Testing Remains Crucial in MDS

November 24th 2021

David Sallman, MD, discusses incorporating mutational testing of patients with myelodysplastic syndrome into clinical practice, and strategies that can be utilized to treat this population.

Saif Shares Insights on Single-Agent PARP Inhibitors and Combination Therapies for Pancreatic Cancer

November 10th 2021

Wasif M. Saif, MD, discusses the evolving role of PARP inhibitors and anticipated trends for research in pancreatic cancer.

Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma, as Efforts Shift to Target Other FGFR Alterations

November 9th 2021

Sameek Roychowdhury, MD, PhD, discusses the efficacy and safety data reported with infigratinib in FGFR2-positive cholangiocarcinoma, nuances to treatment with the agent, and ongoing research efforts to further improve outcomes in this population.

2021 ISGIO Meeting Packed With Multidisciplinary Updates in Gastrointestinal Cancers

November 9th 2021

Gastrointestinal cancer is increasingly viewed through a multidisciplinary lens, and the 2021 International Society of Gastrointestinal Oncology Annual Meeting produced intriguing developments in the armamentarium.

Pembrolizumab Plus Chemoradiation Therapy Elicits Strong Responses in Stage III NSCLC

November 2nd 2021

Salma K. Jabbour, MD, discusses the validity and clinical implications of using pembrolizumab plus platinum chemoradiation in patients with stage III non–small cell lung cancer.

Adjuvant Atezolizumab Provides Potential Standard of Care for PD-L1+ NSCLC

November 2nd 2021

John V. Heymach, MD, PhD, discusses the background of the Impower010 trial, the benefit for patients with PD-L1 levels of at least 1%, and the exciting direction adjuvant therapy in NSCLC is heading.

Cancer Dormancy and Tumor Microenvironment Institute to Take Research Efforts to Greater Heights

October 29th 2021

The Cancer Dormancy and Tumor Microenvironment Institute, which has recently been launched at Albert Einstein Cancer Center, will focus on taking the tumor microenvironment research being done at the center to the next level and to develop novel technologies that can better identify dormant cancer as well as prevent and control recurrent disease.

Additional Efforts Needed to Optimize Treatment With BTK Inhibitors in MCL

October 29th 2021

Bijal Shah, MD, MS, discusses the evolving role of BTK inhibitors in MCL, how to choose among the variety of agents, and the safety concerns that affect treatment decisions.

CoopERA Results Show Benefits of Giredestrant in ER+/HER2– Early Breast Cancer

October 28th 2021

Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

October 21st 2021

Chan Cheah, MBBS, discusses TG-1701 as a more target-specific BTK inhibitor, the outcomes in response rates in the cohorts of the trial, and where future research is headed with this agent.